MA29993B1 - Composition immunogene - Google Patents

Composition immunogene

Info

Publication number
MA29993B1
MA29993B1 MA30522A MA30522A MA29993B1 MA 29993 B1 MA29993 B1 MA 29993B1 MA 30522 A MA30522 A MA 30522A MA 30522 A MA30522 A MA 30522A MA 29993 B1 MA29993 B1 MA 29993B1
Authority
MA
Morocco
Prior art keywords
immunogenic composition
meningitidis
polysaccharide
capsular
serogroups
Prior art date
Application number
MA30522A
Other languages
English (en)
Inventor
Ralph Leon Biemans
Dominique Boutriau
Carine Capiau
Philippe Denoel
Pierre Duvivier
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29993(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29993B1 publication Critical patent/MA29993B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)

Abstract

L'invention concerne une composition immunogène comprenant des polysaccharides capsulaires N. meningitidis différents d'au moins un des sérogroupes A, C, W135 et Y conjugués avec une protéine porteuse afin d'obtenir un conjugué de polysaccharide capsulaire N. meningitidis, la taille moyenne de chaque polysaccharide N. meningitidis étant supérieure à 50kDa.
MA30522A 2005-06-27 2007-12-27 Composition immunogene MA29993B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition

Publications (1)

Publication Number Publication Date
MA29993B1 true MA29993B1 (fr) 2008-12-01

Family

ID=36716943

Family Applications (4)

Application Number Title Priority Date Filing Date
MA30511A MA29602B1 (fr) 2005-06-27 2007-12-26 Composition immunogene
MA30512A MA29603B1 (fr) 2005-06-27 2007-12-26 Procede de fabrication de vaccins
MA30521A MA29569B1 (fr) 2005-06-27 2007-12-27 Composition immunogene
MA30522A MA29993B1 (fr) 2005-06-27 2007-12-27 Composition immunogene

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MA30511A MA29602B1 (fr) 2005-06-27 2007-12-26 Composition immunogene
MA30512A MA29603B1 (fr) 2005-06-27 2007-12-26 Procede de fabrication de vaccins
MA30521A MA29569B1 (fr) 2005-06-27 2007-12-27 Composition immunogene

Country Status (36)

Country Link
US (13) US8329184B2 (fr)
EP (11) EP1896063B2 (fr)
JP (9) JP5297800B2 (fr)
KR (7) KR101359953B1 (fr)
CN (3) CN103083657B (fr)
AP (1) AP2436A (fr)
AR (3) AR056396A1 (fr)
AT (3) ATE516816T1 (fr)
AU (7) AU2006263963B2 (fr)
BE (1) BE2012C042I2 (fr)
BR (5) BRPI0612655B1 (fr)
CA (5) CA2612980C (fr)
CY (5) CY1109996T1 (fr)
DE (1) DE602006013313D1 (fr)
DK (7) DK2283857T3 (fr)
EA (4) EA012506B1 (fr)
ES (9) ES2898451T3 (fr)
FR (1) FR22C1008I2 (fr)
HR (4) HRP20120102T1 (fr)
HU (7) HUE045482T2 (fr)
IL (8) IL187924A (fr)
LT (2) LT2351578T (fr)
LU (2) LU92085I2 (fr)
MA (4) MA29602B1 (fr)
MX (5) MX2007016402A (fr)
MY (3) MY147490A (fr)
NL (2) NL300549I2 (fr)
NO (4) NO345422B1 (fr)
NZ (6) NZ590204A (fr)
PE (6) PE20110096A1 (fr)
PL (8) PL1896061T3 (fr)
PT (8) PT2351578T (fr)
SI (8) SI1896062T1 (fr)
TW (5) TWI422386B (fr)
UA (2) UA95237C2 (fr)
WO (6) WO2007000314A2 (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1946769B1 (fr) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Composition de vaccin multivalente avec dose réduite de Haemophilus influenzae type B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
HUE045482T2 (hu) † 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
CN102973929B (zh) * 2005-09-01 2017-04-26 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
JP5792920B2 (ja) 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
WO2010023216A1 (fr) * 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccin
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP3017826A1 (fr) 2009-03-24 2016-05-11 Novartis AG Combinaisons de protéines de liaison du facteur h méningococcique et de conjugués de saccharides de pneumocoques
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
EP2419129A2 (fr) 2009-04-14 2012-02-22 Novartis AG Compositions pour l'immunisation contre staphylococcus aureus
DK2424562T3 (en) * 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
WO2011041003A2 (fr) * 2009-06-22 2011-04-07 Wyeth Llc Compositions et procédés d'élaboration de compositions immunogènes conjuguées à polysaccharides capsulaires de sérotypes 5 et 8 de staphylococcus aureus
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2519265B1 (fr) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011161653A1 (fr) 2010-06-25 2011-12-29 Novartis Ag Associations de protéines de liaison du facteur h méningococcique
CA2808975C (fr) 2010-08-23 2018-10-30 Wyeth Llc Formulations stables des antigenes rlp2086 de neisseria meningitidis
JP2013538217A (ja) 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2810971C (fr) 2010-09-10 2020-11-03 Novartis Ag Developpements apportes a des vesicules membranaires externes meningococciques
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
CN103533954B (zh) 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2797624A1 (fr) 2011-12-29 2014-11-05 Novartis AG Combinaisons avec adjuvant de protéines méningococciques liant le facteur h
US9198977B2 (en) * 2012-01-30 2015-12-01 Serum Institute Of India Ltd. Immunogenic composition
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
WO2013131983A1 (fr) 2012-03-07 2013-09-12 Novartis Ag Formulations contenant un adjuvant d'antigènes de streptococcus pneumoniae
CA2866406A1 (fr) 2012-03-08 2013-09-12 Novartis Ag Formulations a adjuvant de vaccins de rappel
EP2822584A1 (fr) 2012-03-08 2015-01-14 Novartis AG Vaccins combinés comprenant des agonistes du tlr4
CA2865745C (fr) 2012-03-09 2018-01-09 Pfizer Inc. Compositions de neisseria meningitidis et procedes associes
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
ITMI20121597A1 (it) * 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
CN105142666A (zh) 2012-11-30 2015-12-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
CA2903716C (fr) 2013-03-08 2019-04-09 Pfizer Inc. Polypeptides immunogenes de fusion
US11883478B2 (en) * 2013-03-18 2024-01-30 Glaxosmithkline Biologicals S.A. Method of treatment
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
IN2014DE02450A (fr) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
IL312327B2 (en) * 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
US12616744B2 (en) 2014-01-21 2026-05-05 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (fr) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited Analyse quantitative pour de la 4-pyrrolidinopyridine (4-ppy) dans des vaccins conjugués polyssacharide-protéine
US10407703B2 (en) 2014-04-17 2019-09-10 Medizinische Hochschule Hannover Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
KR20250058066A (ko) * 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
MX2018010920A (es) * 2016-03-15 2019-03-06 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
CN109890413B (zh) * 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
US11027005B2 (en) * 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (fr) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Composition de vaccin méningococcique tétravalente et son procédé de préparation
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CA3155669A1 (fr) 2019-09-27 2021-04-01 Pfizer Inc. Compositions de neisseria meningitidis et methodes associees
BR112022008761A2 (pt) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
US20240000958A1 (en) 2020-11-13 2024-01-04 Glaxosmithkline Biologicals Sa Novel carriers and conjugation methods
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
CN121569027A (zh) 2023-07-21 2026-02-24 葛兰素史克生物有限公司 免疫原性组合物

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (fr) 1979-09-21 1986-04-16 Hitachi, Ltd. Interrupteur à semiconducteur
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
HU193083B (en) * 1984-02-22 1987-08-28 Sandoz Ag Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
JPH03504564A (ja) 1988-05-31 1991-10-09 ベアトリーセ　ケーニッヒ‐ハウク 棚装置
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (fr) 1989-01-17 1990-07-17 Antonello Pessi Peptides synthetiques et leur utilisation comme porteurs universels pour la preparation de conjugats immunogenes convenant a la mise au point de vaccins synthetiques
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
RO111416B1 (ro) 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (fr) 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
CA2059693C (fr) 1991-01-28 2003-08-19 Peter J. Kniskern Antigenes polysaccharides de streptococcus pneumoniae
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
EP0625910B1 (fr) 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Structure immunogene a double vecteur
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
JP3506431B2 (ja) 1992-05-06 2004-03-15 プレジデント アンド フェローズ オブ ハーバード カレッジ ジフテリア毒素受容体結合領域
JP3626996B2 (ja) 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ATE176157T1 (de) 1992-10-27 1999-02-15 American Cyanamid Co Pädiatrische kombinationsvakzine mit verbesserter immunogenizität jeder vakzine komponente
AU5951894A (en) 1992-12-14 1994-07-04 Western Atlas International, Inc. Removable piston bore liner for hydraulically actuated seismic vibrator
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
EP0720485B1 (fr) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procede permettant d'activer un glucide soluble a l'aide de nouveaux reactifs cyanylants pour produire des structures immunogenes
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
DE69628418T2 (de) 1995-03-22 2004-04-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
NZ311000A (en) 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
EP0833662B2 (fr) 1995-06-23 2011-01-26 SmithKline Beecham Biologicals S.A. Composition vaccinale comprenant un antigène polyosidique conjugué, de hemophilus influenzae B adsorbé sur du phosphate d'aluminium
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
EP0936601B1 (fr) 1996-10-23 2002-04-24 Matsushita Electric Industrial Co., Ltd. Disque optique
ATE348887T1 (de) 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigene und impfstoffe
WO1998026799A1 (fr) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vaccin conjugue contre la salmonella paratyphi a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
BR9714980A (pt) 1997-09-15 2001-11-06 Pasteur Merieux Msd Vacinas multivalentes
WO1999013905A1 (fr) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Mutants de poche de fixation de recepteur d'hemagglutinine de virus de grippe a
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (fr) 1998-03-10 1999-09-10 American Cyanamid Company Conjugues antigeniques de lipolysaccharides de bacteries gram-negatives
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
WO2000033882A1 (fr) † 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Conjugue vaccinal vi-repa pour l'immunisation contre la salmonella typhi
CA2355364C (fr) 1998-12-21 2014-03-18 Medimmune, Inc. Proteines de streptococcus pneumoniae et fragments immunogenes pour vaccins
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
WO2000050006A2 (fr) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions a macromolecules et microparticules adsorbees
CA2366152A1 (fr) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccin
WO2000061761A2 (fr) 1999-04-09 2000-10-19 Techlab, Inc. Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
EP1192242B1 (fr) 1999-06-25 2010-05-05 Wyeth Holdings Corporation Production d'une forme lipidee de lipoproteines, associees a peptidoglycane, de bacteries gram negatif
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
EP2292263A3 (fr) 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés pour la stabilisation de molécules biologiques lors de la lyophilisation
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
EP1946769B1 (fr) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Composition de vaccin multivalente avec dose réduite de Haemophilus influenzae type B
MXPA03000822A (es) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
CA2435681C (fr) * 2001-01-23 2011-06-21 Aventis Pasteur Vaccin meningococcique polyvalent prrepare avec un conjugue de polysaccharide et de proteine
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
CA2479118A1 (fr) 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants de la proteine p4 de haemophilus influenzae non typable a activite enzymatique reduite
ES2616180T3 (es) * 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
NZ536859A (en) 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2351579B1 (fr) * 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Vaccins incluant du NadA oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes
CN1401328A (zh) 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
CA2503871C (fr) * 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. Composition immunogene induisant une reponse immunitaire contre le virus de la poliomyelite
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
DK1587537T3 (da) * 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
MXPA05009579A (es) * 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Proceso de purificacion para citolisina bacteriana.
EP1603950A2 (fr) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene
AU2004240558A1 (en) * 2003-05-07 2004-12-02 Aventis Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
MXPA05014171A (es) 2003-06-23 2007-02-21 Sanofi Pasteur Inc Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
AU2004263135B2 (en) * 2003-08-06 2010-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EP1656687A2 (fr) * 2003-08-21 2006-05-17 Applera Corporation Reduction d'une interaction due a la matrice pour analyse par spectrometrie de masse maldi
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
AU2004277342B2 (en) 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
US7628995B2 (en) 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
RU2379052C2 (ru) * 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
US20060121055A1 (en) 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
IL308456A (en) * 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
PL1885734T3 (pl) * 2005-05-06 2015-08-31 Novartis Ag Immunogeny dla szczepionek przeciwko Meningitidis-A
HUE045482T2 (hu) * 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
CN102973929B (zh) 2005-09-01 2017-04-26 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
EP2208999B1 (fr) * 2005-09-05 2014-08-27 GlaxoSmithKline Biologicals SA Essai d'activité bactéricide sérique pour des antisérums spécifiques de n. méningitidis
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
JP5792920B2 (ja) * 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
WO2007071786A2 (fr) 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Vaccin
KR101838938B1 (ko) * 2006-03-17 2018-03-15 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
NZ570805A (en) * 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
AU2007263531B2 (en) * 2006-06-29 2012-03-15 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
CA2658393A1 (fr) 2006-07-21 2008-01-24 The Regents Of The University Of California Compositions polypeptidiques retrovirales endogenes humaines et leurs procedes d'utilisation
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
JP4858611B2 (ja) 2007-03-14 2012-01-18 コニカミノルタビジネステクノロジーズ株式会社 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
IN2009KN04098A (fr) 2007-06-04 2015-08-28 Novartis Ag
EA200901578A1 (ru) * 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2010023216A1 (fr) 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccin
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
US8974799B2 (en) * 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CA2792691A1 (fr) * 2010-03-11 2011-09-15 Glaxosmithkline Biologicals S.A. Composition immunogene ou vaccin contre une bacterie gram negative, par exemple, infection ou maladie neisserial
JP5144836B2 (ja) * 2010-06-11 2013-02-13 パナソニック株式会社 語音聴取の評価システム、その方法およびそのプログラム
RU2636350C2 (ru) * 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
GB2495341B (en) * 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
US9198977B2 (en) * 2012-01-30 2015-12-01 Serum Institute Of India Ltd. Immunogenic composition
EP2852414B9 (fr) * 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Conjugué de sérogroupe x de méningocoque
WO2014001328A1 (fr) 2012-06-25 2014-01-03 Nadiro A/S Unité de déploiement de canot de sauvetage
EP2928489B1 (fr) * 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Composition immunogène
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
BR112017002183A2 (pt) * 2014-08-05 2018-01-16 Glaxosmithkline Biologicals S.A. conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CN109890413B (zh) * 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
SG11201906519RA (en) * 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
BR112020000999A2 (pt) * 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação

Also Published As

Publication number Publication date
TW200730187A (en) 2007-08-16
SI2283857T1 (sl) 2019-11-29
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
AU2006263964B2 (en) 2010-05-20
KR20130122810A (ko) 2013-11-08
EP2201961A1 (fr) 2010-06-30
AU2006263936A1 (en) 2007-01-04
US20190298822A1 (en) 2019-10-03
EA012528B1 (ru) 2009-10-30
EP2878307B1 (fr) 2019-07-24
ES2741529T3 (es) 2020-02-11
EP2351578B1 (fr) 2017-01-18
SI1896065T2 (sl) 2014-12-31
US10245317B2 (en) 2019-04-02
AU2006263944A1 (en) 2007-01-04
HUE031380T2 (en) 2017-07-28
PE20110072A1 (es) 2011-02-04
CA2612980C (fr) 2019-01-15
BRPI0612655A2 (pt) 2010-11-30
TW201336507A (zh) 2013-09-16
LUC00247I2 (fr) 2024-10-04
EP1896062B1 (fr) 2010-03-31
DE602006013313D1 (de) 2010-05-12
PE20070499A1 (es) 2007-05-21
KR20080030577A (ko) 2008-04-04
MX2007016403A (es) 2008-03-07
TWI422386B (zh) 2014-01-11
LTPA2012019I1 (lt) 2012-11-26
UA95237C2 (uk) 2011-07-25
JP2008543905A (ja) 2008-12-04
NZ564370A (en) 2011-10-28
PL2283857T3 (pl) 2020-02-28
MX2007016236A (es) 2008-03-07
KR101532068B1 (ko) 2015-06-29
NZ590204A (en) 2012-02-24
WO2007000314A2 (fr) 2007-01-04
HRP20120102T1 (hr) 2012-02-29
EP1896063B1 (fr) 2011-12-14
IL188072A0 (en) 2008-03-20
AU2010203115C1 (en) 2013-05-02
JP5965512B2 (ja) 2016-08-03
EP1896066B1 (fr) 2021-10-27
HK1116414A1 (en) 2008-12-24
TW201414490A (zh) 2014-04-16
EA200702577A1 (ru) 2008-06-30
MY147490A (en) 2012-12-14
ATE462444T1 (de) 2010-04-15
PL1896062T3 (pl) 2010-08-31
SI1896062T1 (sl) 2010-07-30
WO2007000342A2 (fr) 2007-01-04
ES2662651T3 (es) 2018-04-09
HUS000497I2 (hu) 2021-03-29
BRPI0612669B8 (pt) 2021-05-25
PL1896065T5 (pl) 2014-12-31
KR101321056B1 (ko) 2013-10-30
WO2007000343A2 (fr) 2007-01-04
BRPI0612655A8 (pt) 2018-01-30
DK1896063T3 (da) 2012-03-19
UA95238C2 (uk) 2011-07-25
JP2013018798A (ja) 2013-01-31
WO2007000343A3 (fr) 2007-05-31
EP3009146A1 (fr) 2016-04-20
EP3009146B1 (fr) 2021-10-20
AU2006263944B2 (en) 2012-03-01
HUE046905T2 (hu) 2020-03-30
PE20070123A1 (es) 2007-02-08
NO20076343L (no) 2008-03-25
MY147783A (en) 2013-01-31
IL188045A0 (en) 2008-03-20
EP1896061A2 (fr) 2008-03-12
US8329184B2 (en) 2012-12-11
TWI537001B (zh) 2016-06-11
IL187924A (en) 2011-11-30
IL213795A0 (en) 2011-07-31
HUE056842T2 (hu) 2022-03-28
NO20076363L (no) 2008-03-26
EP2351578A1 (fr) 2011-08-03
US11241495B2 (en) 2022-02-08
EP2283857B1 (fr) 2019-07-24
JP2013209395A (ja) 2013-10-10
CA2612957C (fr) 2016-07-19
WO2007000322A1 (fr) 2007-01-04
EP2878307A1 (fr) 2015-06-03
PT1896062E (pt) 2010-05-17
US20180064806A1 (en) 2018-03-08
DK2878307T3 (da) 2019-10-07
ES2621780T3 (es) 2017-07-05
WO2007000342A3 (fr) 2007-05-31
BRPI0612654A2 (pt) 2012-10-02
LT2351578T (lt) 2017-04-10
HRP20100211T1 (hr) 2010-05-31
MX2007016402A (es) 2008-03-07
WO2007000341A3 (fr) 2007-05-31
US9931397B2 (en) 2018-04-03
CA2612980A1 (fr) 2007-01-04
SI1896065T1 (sl) 2011-10-28
HUS1200023I1 (hu) 2021-03-29
US8431136B2 (en) 2013-04-30
ES2747025T3 (es) 2020-03-09
JP2015134829A (ja) 2015-07-27
JP2008543904A (ja) 2008-12-04
BRPI0612654B1 (pt) 2021-05-04
PT1896061T (pt) 2019-08-01
CA2611960A1 (fr) 2007-01-04
NZ564605A (en) 2011-01-28
EP1896063B2 (fr) 2016-03-02
PT2878307T (pt) 2019-10-24
EA012506B1 (ru) 2009-10-30
AP2436A (en) 2012-08-31
BRPI0612656B1 (pt) 2021-09-08
TW200738259A (en) 2007-10-16
US20090041802A1 (en) 2009-02-12
US9789179B2 (en) 2017-10-17
US20080193476A1 (en) 2008-08-14
AU2010203115A1 (en) 2010-08-12
CY1109996T1 (el) 2014-09-10
EA013374B1 (ru) 2010-04-30
TWI407970B (zh) 2013-09-11
HUE047211T2 (hu) 2020-04-28
NL300549I2 (fr) 2017-01-03
KR101351873B1 (ko) 2014-02-17
NO345305B1 (no) 2020-12-07
NZ564607A (en) 2011-06-30
PL1896063T3 (pl) 2012-04-30
EP1896061B1 (fr) 2019-06-12
PL3009146T3 (pl) 2022-02-07
EP1896066B8 (fr) 2022-01-19
US20100215686A1 (en) 2010-08-26
CA2611964C (fr) 2016-11-08
WO2007000341A2 (fr) 2007-01-04
US20150044253A1 (en) 2015-02-12
CY2012027I2 (el) 2015-10-07
ES2898451T3 (es) 2022-03-07
EA200702575A1 (ru) 2008-06-30
PT2283857T (pt) 2019-10-24
BRPI0612656A2 (pt) 2010-11-30
WO2007000342A8 (fr) 2008-07-10
BE2012C042I2 (fr) 2021-07-19
ATE536884T1 (de) 2011-12-15
PL1896061T3 (pl) 2020-02-28
AU2010203115B2 (en) 2012-03-15
IL213795A (en) 2013-05-30
NO345422B1 (no) 2021-01-25
IL213718A (en) 2013-07-31
JP5718960B2 (ja) 2015-05-13
NL301151I2 (nl) 2025-12-15
AU2006263965A1 (en) 2007-01-04
JP5297800B2 (ja) 2013-09-25
IL188046A0 (en) 2008-03-20
HK1114011A1 (en) 2008-10-24
PL1896065T3 (pl) 2011-12-30
ES2750243T3 (es) 2020-03-25
HRP20110567T4 (xx) 2015-01-16
DK1896061T3 (da) 2019-08-26
US9486515B2 (en) 2016-11-08
CY1112698T1 (el) 2016-02-10
MX2007016237A (es) 2008-03-07
BRPI0612654B8 (pt) 2021-05-25
EA200702574A1 (ru) 2008-06-30
CA2611960C (fr) 2015-05-05
IL214657A0 (en) 2011-09-27
BRPI0612670B1 (pt) 2020-04-28
EP1896064A2 (fr) 2008-03-12
KR20080018226A (ko) 2008-02-27
US20200000911A1 (en) 2020-01-02
EP1896066A2 (fr) 2008-03-12
JP5769688B2 (ja) 2015-08-26
US20090252759A1 (en) 2009-10-08
EP1896065A2 (fr) 2008-03-12
CA2612963C (fr) 2016-10-18
HRP20170457T1 (hr) 2017-05-19
US8398983B2 (en) 2013-03-19
EP1896065B1 (fr) 2011-07-20
EP2201961B1 (fr) 2018-01-24
ES2340711T3 (es) 2010-06-08
NZ564606A (en) 2010-10-29
JP2013107913A (ja) 2013-06-06
DK2351578T3 (en) 2017-04-24
ES2377075T5 (es) 2016-04-29
US20090136541A1 (en) 2009-05-28
CA2612963A1 (fr) 2007-01-04
HUE045482T2 (hu) 2019-12-30
WO2007000327A1 (fr) 2007-01-04
CN103083657B (zh) 2016-06-08
US10166287B2 (en) 2019-01-01
MA29602B1 (fr) 2008-07-01
LTC1896065I2 (lt) 2025-06-10
CY2012027I1 (el) 2015-10-07
JP5037503B2 (ja) 2012-09-26
AP2007004274A0 (en) 2007-12-31
SI1896061T1 (sl) 2019-10-30
BRPI0612669B1 (pt) 2019-08-13
CA2611964A1 (fr) 2007-01-04
ES2377075T3 (es) 2012-03-22
SI3009146T1 (sl) 2022-02-28
KR101351870B1 (ko) 2014-02-17
MX2007016405A (es) 2008-03-07
AU2006263963B2 (en) 2010-05-13
HK1116413A1 (en) 2008-12-24
WO2007000314A3 (fr) 2007-05-31
NO342815B1 (no) 2018-08-13
DK2283857T3 (da) 2019-10-28
JP2008543908A (ja) 2008-12-04
CN102218138A (zh) 2011-10-19
EP1896063A1 (fr) 2008-03-12
BRPI0612670B8 (pt) 2021-05-25
PE20142165A1 (es) 2015-01-09
US20170065714A1 (en) 2017-03-09
US8846049B2 (en) 2014-09-30
KR20080025184A (ko) 2008-03-19
NO344452B1 (no) 2019-12-09
MA29603B1 (fr) 2008-07-01
CN103083657A (zh) 2013-05-08
LU92085I9 (fr) 2019-01-04
JP5280199B2 (ja) 2013-09-04
PL2351578T3 (pl) 2017-07-31
NZ564371A (en) 2010-05-28
CA2612957A1 (fr) 2007-01-04
AR056396A1 (es) 2007-10-10
BRPI0612669A2 (pt) 2010-11-30
TWI477283B (zh) 2015-03-21
SI2351578T1 (sl) 2017-05-31
ATE516816T1 (de) 2011-08-15
US20130004532A1 (en) 2013-01-03
JP5731737B2 (ja) 2015-06-10
EP2283857A1 (fr) 2011-02-16
FR22C1008I1 (fr) 2022-04-29
NO20076350L (no) 2008-03-26
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
CY1118646T1 (el) 2017-07-12
AU2010212417A1 (en) 2010-09-09
CN102526723B (zh) 2017-07-07
HUS2200002I1 (hu) 2022-12-28
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
KR20130086087A (ko) 2013-07-30
IL213718A0 (en) 2011-07-31
PT1896065E (pt) 2011-08-31
HRP20110567T1 (en) 2011-09-30
EA200702576A1 (ru) 2008-06-30
CN102526723A (zh) 2012-07-04
MY148110A (en) 2013-02-28
SI1896063T1 (sl) 2012-03-30
PT3009146T (pt) 2021-11-30
US20080199490A1 (en) 2008-08-21
EA012214B1 (ru) 2009-08-28
EP1896062A1 (fr) 2008-03-12
IL188072A (en) 2017-07-31
KR101408113B1 (ko) 2014-06-16
AU2006263964A1 (en) 2007-01-04
DK1896065T4 (da) 2014-10-20
DK1896062T3 (da) 2010-06-28
US9358279B2 (en) 2016-06-07
EP1896065B2 (fr) 2014-09-03
JP2008543907A (ja) 2008-12-04
AR056397A1 (es) 2007-10-10
IL188046A (en) 2012-03-29
BRPI0612656A8 (pt) 2018-01-23
CY1111827T1 (el) 2015-10-07
AU2006263936B2 (en) 2010-05-20
US8883163B2 (en) 2014-11-11
AU2006263963A1 (en) 2007-01-04
KR20080024222A (ko) 2008-03-17
PE20070163A1 (es) 2007-03-01
BRPI0612670A2 (pt) 2010-11-30
PE20110096A1 (es) 2011-03-07
KR101359953B1 (ko) 2014-02-21
FR22C1008I2 (fr) 2024-01-19
LU92085I2 (fr) 2012-12-19
SI2878307T1 (sl) 2019-11-29
JP2008543909A (ja) 2008-12-04
IL222346A (en) 2015-07-30
PT1896063E (pt) 2012-02-13
AR053935A1 (es) 2007-05-23
HK1206587A1 (en) 2016-01-15
US20130171188A1 (en) 2013-07-04
IL187924A0 (en) 2008-03-20
MA29569B1 (fr) 2008-06-02
ES2901378T3 (es) 2022-03-22
DK1896065T3 (da) 2011-08-29

Similar Documents

Publication Publication Date Title
EA200702574A1 (ru) Иммуногенная композиция
HRP20090607T8 (en) Combined meningococcal conjugates with common carrier protein
IL227934A (en) An immunogenic preparation containing polysaccharide or oligosaccharide from s. type 5 or 8 aureus and various aspects related to it
CY1112763T1 (el) Υπο-ακετυλιωμενα και υπερ-ακετυλιωμενα μηνιγγοκοκκικα καψικα σακχαριδια
WO2006032500A3 (fr) Composition immunogene
RU2007102016A (ru) Пространственный анализ конъюгатов сахаридов с помощью gpc и sec-mals
ZA202310611B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP1725872B8 (fr) Analyse de vaccins saccharidiques sans interference
PE20110065A1 (es) Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
EA200801368A1 (ru) Конъюгатные вакцины
MA29459B1 (fr) Vaccins
NO20081879L (no) Nye kvaternaere polymerer
UA95075C2 (uk) Імуногенна композиція
FR3109310A1 (fr) Compositions capillaires comprenant un polysaccharide modifié et un dérivé de cellulose cationique
ATE432609T1 (de) Selbstfahrende landmaschine
TR200606837U (tr) Burçlu, kaynaksız, ayarlı menteşe.
黄雅钦 et al. Antibacterial Activity of Novel Complex of Gelatin Hydrolysate and Cerium
Burch Memo-February 21, 2002 University Senate Minutes
TR200502639U (tr) Hareket tertibatı.
TH81514S (th) ชิ้นส่วนเครื่องผลิตถุงมือ